Produced at company’s USA facility, solution helps safeguard tubes for topical disinfectants, eye ointments & creams, and oral care products.
Oberdiessbach, Switzerland – Hoffmann Neopac, a global provider of high-quality packaging for the pharmaceutical, beauty and oral care industry, has introduced a tamper-evident version of its Nozzle Tube solution. Ideal for topical disinfectant solutions, eye ointments, breams and gels, and certain oral care products, the tubes are available with 1.1mm orifices, and feature a ribbed cap for ease of use.
The tubes’ tamper-evident closure helps guarantee supply chain integrity for end user safety and reassurance. Available in sizes from 13.5-19mm for volumes from 3-8ml, the tubes utilize Neopac’s Polyfoil® technology, comprising a proprietary blend of materials providing advanced barrier properties for products requiring ample protection against moisture, oxygen and other potentially harmful external factors.
The small tubes are manufactured at Neopac’s production plant in Wilson, North Carolina. The 37,000-square-foot plant features a high-speed tube line capable of producing some 80 million tubes annually. The facility allows Neopac to best serve the needs of the North American market in a twofold capacity: in the small tubes niche – especially in the pharma, cosmetics and animal health sectors – and also for emerging applications such as cannabis-based creams and liquids with child-resistant caps.
“The tamper-evident nozzle tubes help prevent counterfeiting and other illicit actions even in the smallest of tube solutions – a niche for which such safeguarding measures can be difficult to implement given the package’s tiny size,” said Jackie De Rose, who recently joined the company as a new US Sales Manager. “In addition, producing these tubes at our U.S. facility provides brand owners throughout North America with expedited shipping and consistent availability.”
Neopac’s tamper-evident Nozzle Tube meets production hygiene standards ISO 9001 & ISO 15378, and its materials comply with FDA 21 CFR USPVI.
For more information, visit www.neopac.com.